Quantitative gDNA TCR/BCR Sequencing with RepSeq IQ™
Quantitative gDNA TCR/BCR Sequencing with RepSeq IQ™
Unveil the adaptive immune response with TCR/BCR profiling and single-cell paired-chain V(D)J analysis for biomarker discovery and therapeutic development
Immune repertoire sequencing provides insights into immune history and diversity, neutralizing antibodies, antigen specificity, and clonal dynamics with the potential to transform overall management of immune-mediated diseases and therapies.
Standard immune repertoire sequencing approaches are limited by subtype restrictions, lack of reproducibility, high error rates, insufficient capture of rare clones, and limited data analysis tools for mapping repertoire diversity and clonality networks.
See why iRepertoire is the most trusted and comprehensive source for immune enlightenment.
We offer a complete suite of adaptive immune receptor profiling and data analysis solutions. Each platform workflow combines proprietary chemistry with optimized analytics to reveal the true diversity of the adaptive immune system.
While other platforms require multiple reactions to profile different receptor chains or limit analysis to DNA or RNA alone, iRepertoire’s dam-PCR technology simultaneously amplifies all seven chains (TCRa, TCRB, TCRy, TCR6, IgH, IgK, IgL) with UMI- based error correction. The unique capability delivers the complete immune picture your research demands, without compromising on sensitivity or amplification bias.
Capture therapeutically relevant cognate TCR or BCR pairing from FACS-isolated single cells with our iPair platform, designed for researchers who need full-length, physically paired sequences without investing in expensive single-cell platforms.
We’ve analyzed immune repertoires since 2009, publishing landmark studies and supporting dozens of clinical programs. Our scientists don’t just generate data; they partner with you to extract biological meaning and accelerate decision-making.
Our immune repertoire profiling solutions empower discovery, preclinical, and clinical teams across therapeutic areas. See how we enable confident biomarker identification and therapeutic development for each.
Comprehensive TCR/ BCR repertoire and gene expression insights to track treatment response, reveal biomarkers of efficacy or toxicity, and support data-driven clinical decisions.
Cell therapy optimization and quality control with multi-omic immune profiling that validates manufacturing consistency, confirms therapeutic phenotype, and de-risks clinical development.
Advance infectious disease therapeutics by mapping rare antigen-specific B- and T-cell responses, defining host immune signatures, and guiding the discovery of vaccines and monoclonal antibodies.
Uncover autoimmune disease biomarkers by profiling rare B and T-cell clones and immune repertoires-delivering reproducible insights into disease mechanisms, diagnostics, and treatment response prediction.
Precisely quantify vaccine-induced TCR/BCR responses with ultra-sensitive bulk and single-cell profiling. Detect rare antigen-specific clonotypes and evaluate vaccine efficacy across infectious-disease and cancer programs with RepSeq+ and iPair.
Precisely track alloreactive TCR/BCR responses to evaluate graft compatibility, rejection risk, and post-transplant immune recovery. Detect early clonal expansions and monitor long-term immune stability with ultra-sensitive bulk and single-cell profiling powered by RepSeq+ and iPair.
Founded by immunologists for immunologists at HudsonAlpha Institute for Biotechnology, we’ve never forgotten that behind every sample is a scientific question that matters. Our technology is sophisticated, but our approach is simple: deliver the most complete, accurate immune profiling data possible, and partner with you to extract biological meaning. Our three main core values set us apart from other companies as we strive to create true partnerships with our customers.
iRepertoire has been the scientists’ choice for immune repertoire analysis, offering accuracy, reproducibility, and actionable insights. We have partnered with top institutions to develop the next generation of immune-based biomarkers and therapeutics. Explore who our partners are or read our publications to learn more about our contributions.
